Fertile ground for regenerative medicine and personalized patient care
The Netherlands’ high concentration of world-leading researchers, business-oriented R&D facilities, and supportive government make the country an ideal base for companies focused on solving global life sciences and healthcare issues and treating patients around the world.
“We always had the intention to grow in Europe and had the Netherlands in sight because the Dutch MPS ecosystem is very active both academically and industry-wise,” said Aydın Öztunali, CEO and co-founder of Initio Cell.
“We visited various science parks in different countries, and the Leiden Bioscience Park was by far the best. The infrastructure and close collaboration with academia was present, all companies were in compatible life science fields, and maybe the most important was the people factor. The Leiden Bioscience Park administration is there to help us grow with a sincerely friendly and resourceful attitude.”
Boasting secure connections between the private sector, government, academia, and patients, the Dutch “quadruple helix” approach provides businesses like Initio Cell with the right environment for innovation in R&D.
Revolutionizing the field of drug discovery
At the forefront of transforming the pharmaceutical industry, Initio Cell’s organ-on-chip tech has the potential to successfully mimic in-vivo conditions, allowing for functional cellular phenotyping and advancing precision medicine. With this technology, it’s possible to create microenvironments resembling various tissues.